% Generated by roxygen2: do not edit by hand
% Please edit documentation in R/biopsysimulation.h.R
\name{biopsysimulation}
\alias{biopsysimulation}
\title{Biopsy Simulation Analysis}
\usage{
biopsysimulation(
  data,
  wholesection,
  biopsy1,
  biopsy2,
  biopsy3,
  biopsy4,
  biopsies,
  spatial_id,
  analysis_type = "comprehensive",
  sampling_strategy = "unknown",
  cv_threshold = 20,
  correlation_threshold = 0.8,
  show_variability_plots = TRUE,
  variance_components = TRUE,
  power_analysis = FALSE,
  generate_recommendations = TRUE
)
}
\arguments{
\item{data}{the data as a data frame}

\item{wholesection}{Biomarker measurement from entire tissue section.
Example: Ki67 proliferation index (0-100\\%), ER/PR expression (0-8 Allred
score), HER2 expression (0-3+ intensity), or quantitative molecular
biomarker values.}

\item{biopsy1}{Biomarker measurement from first simulated core biopsy
sample. Should represent same biomarker as whole section measurement.
Example: Ki67 \\% from 2mm core biopsy #1.}

\item{biopsy2}{second simulated biopsy measurement}

\item{biopsy3}{third simulated biopsy measurement}

\item{biopsy4}{fourth simulated biopsy measurement}

\item{biopsies}{additional simulated biopsy measurements}

\item{spatial_id}{identifier for spatial regions or tissue areas}

\item{analysis_type}{primary focus of biopsy simulation analysis}

\item{sampling_strategy}{biopsy sampling strategy used}

\item{cv_threshold}{Coefficient of variation threshold for acceptable
sampling variability. Typical clinical values: 15-25\\% for
immunohistochemistry (Ki67, ER, PR), 10-20\\% for molecular assays, 20-30\\%
for heterogeneous markers (HER2, PD-L1). Lower values indicate more
stringent quality requirements.}

\item{correlation_threshold}{Minimum Spearman correlation between biopsy
and whole section measurements. Clinical guidelines: ≥0.80 excellent
agreement, ≥0.70 good agreement, ≥0.60 moderate agreement, <0.60 poor
agreement. Higher values indicate better representativeness of biopsy
samples.}

\item{show_variability_plots}{display plots showing sampling variability}

\item{variance_components}{perform variance component decomposition}

\item{power_analysis}{perform power analysis for sample size
recommendations}

\item{generate_recommendations}{provide recommendations for optimal
sampling strategy}
}
\value{
A results object containing:
\tabular{llllll}{
\code{results$interpretation} \tab \tab \tab \tab \tab a html \cr
\code{results$report_sentences} \tab \tab \tab \tab \tab Pre-formatted sentences ready for clinical reports and publications \cr
\code{results$assumptions} \tab \tab \tab \tab \tab Analysis assumptions, data requirements, and methodological considerations \cr
\code{results$reproducibilitytable} \tab \tab \tab \tab \tab Correlation and reliability metrics \cr
\code{results$samplingbiastable} \tab \tab \tab \tab \tab Systematic bias assessment between methods \cr
\code{results$variancetable} \tab \tab \tab \tab \tab Sources of measurement variability \cr
\code{results$poweranalysistable} \tab \tab \tab \tab \tab Sample size recommendations and power calculations \cr
\code{results$spatialanalysistable} \tab \tab \tab \tab \tab Variability across spatial regions \cr
\code{results$biopsyplot} \tab \tab \tab \tab \tab Distribution comparison across methods \cr
\code{results$variabilityplot} \tab \tab \tab \tab \tab Coefficient of variation by case \cr
\code{results$spatialplot} \tab \tab \tab \tab \tab Spatial distribution of biomarker values \cr
}

Tables can be converted to data frames with \code{asDF} or \code{\link{as.data.frame}}. For example:

\code{results$reproducibilitytable$asDF}

\code{as.data.frame(results$reproducibilitytable)}
}
\description{
Biopsy Simulation Analysis
}
